228 related articles for article (PubMed ID: 24797790)
1. [Cost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in France].
Chiche L; Perrin A; Stern L; Kutikova L; Cohen-Nizard S; Lefrère F
Transfus Clin Biol; 2014 May; 21(2):85-93. PubMed ID: 24797790
[TBL] [Abstract][Full Text] [Related]
2. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
López MF; Mingot ME; Valcárcel D; Vicente García V; Perrin A; Campos Tapias I
Med Clin (Barc); 2015 May; 144(9):389-96. PubMed ID: 24565604
[TBL] [Abstract][Full Text] [Related]
3. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
Lee D; Thornton P; Hirst A; Kutikova L; Deuson R; Brereton N
Appl Health Econ Health Policy; 2013 Oct; 11(5):457-69. PubMed ID: 23857462
[TBL] [Abstract][Full Text] [Related]
5. Cost per response analysis of strategies for chronic immune thrombocytopenia.
Fust K; Parthan A; Li X; Sharma A; Zhang X; Campioni M; Lin J; Wang X; Zur R; Cetin K; Eisen M; Chandler D
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP294-SP302. PubMed ID: 30020741
[TBL] [Abstract][Full Text] [Related]
6. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
[TBL] [Abstract][Full Text] [Related]
7. A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
Dolph M; Roy A; Bhor M; Hearnden J; Kwon CS; Forsythe A; Tremblay G; Briggs A
J Comp Eff Res; 2018 Aug; 7(8):775-784. PubMed ID: 29848048
[No Abstract] [Full Text] [Related]
8. [Economic evaluation of Thrombopoietin Receptor Agonists in the treatment of chronic primary immune thrombocytopenia].
Parrondo J; Grande C; Ibáñez J; Palau J; Páramo JA; Villa G
Farm Hosp; 2013; 37(3):182-91. PubMed ID: 23789796
[TBL] [Abstract][Full Text] [Related]
9. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
[TBL] [Abstract][Full Text] [Related]
11. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).
Sanz MA; Aledort L; Mathias SD; Wang X; Isitt JJ
Value Health; 2011 Jan; 14(1):90-6. PubMed ID: 21211490
[TBL] [Abstract][Full Text] [Related]
12. Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada.
Pettigrew M; Garces K; Deuson R; Kassis J; Laroche V
J Med Econ; 2013; 16(2):318-26. PubMed ID: 23216012
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.
Kuter DJ; Mathias SD; Rummel M; Mandanas R; Giagounidis AA; Wang X; Deuson RR
Am J Hematol; 2012 May; 87(5):558-61. PubMed ID: 22460421
[TBL] [Abstract][Full Text] [Related]
14. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
15. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
[No Abstract] [Full Text] [Related]
16. Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.
Donga PZ; Bilir SP; Little G; Babinchak T; Munakata J
J Med Econ; 2017 Nov; 20(11):1200-1206. PubMed ID: 28882075
[TBL] [Abstract][Full Text] [Related]
17. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
[No Abstract] [Full Text] [Related]
18. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
[TBL] [Abstract][Full Text] [Related]
19. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
[TBL] [Abstract][Full Text] [Related]
20. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].
Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T
Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804
[No Abstract] [Full Text] [Related]
[Next] [New Search]